TWST Maintained by Canaccord Genuity -- Price Target Raised to $
Canaccord Genuity raised its price target for Twist Bioscience (TWST) to $205.00 from $120.00, maintaining a 'Buy' rating. The company's stock is currently trading at $148.22, which is 174.4% overvalued according to GF Value™. Twist Bioscience has a GF Score™ of 70/100, indicating strong growth potential but weaknesses in profitability and valuation. Insiders have sold $119.57 million worth of shares in the last three months.
How this was made
The 30-second read
Why it matters
The analyst's price target increase reflects optimism on growth, but valuation concerns and insider sell pressure may limit upside.
Market read
Analyst target raise could prompt short-term buying, but valuation and insider activity present risk.
What to watch
Potential downside from sustained unprofitability and a P/S ratio far above historical norms.
Background
Twist Bioscience is a synthetic DNA manufacturer with a market cap of ~$9.8B, currently unprofitable and trading at a high price-to-sales multiple.
Ticker impact
Canaccord Genuity raised Twist Bioscience's price target from $120 to $205 and maintained a Buy rating.
likely upward pressure as investors price in the higher target
The substantial target increase signals bullish outlook, but the stock is already overvalued per GF metrics, tempering the upside.
Market effects
May boost sentiment for synthetic biology and biotech peers.
Limited to US biotech investors.
Low; primarily affects US-listed biotech exposure.
Counterpoint
High valuation and heavy insider selling suggest caution despite the target raise.
Key entities
- Analyst FirmCanaccord Genuity
Provided the rating update and new price target.
